Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat.
Orlistat is a potent and selective inhibitor of gastrointestinal lipases. The drug is designed for the treatment of obesity. The effect on dietary fat absorption of orlistat after administration of divided doses spread over 2 hours from mid-meal, in comparison with that after administration of a full dose mid-meal, was investigated in a randomized, single-blind study including 16 hospitalized healthy males. After a 5-day run-in, to accustom the subjects to a diet of 2350 kcal and 76 g fat per day and to establish baseline fecal fat excretion, subjects received, in two parallel groups of eight over 8 days, three times a day 80 mg orlistat at mid-meal, and placebo at mid-meal and 0.5, 1, and 2 hr after mid-meal (group A), or placebo at mid-meal, and 20 mg orlistat at mid-meal and 0.5, 1, and 2 hr after mid-meal (group B). Feces were collected to measure total fat excretion. The mean (SD) of fecal fat in percent of dietary fat, after deduction of pretreatment fecal fat, was (%) 36.1 (4.2) and 37.0 (9.3) in groups A and B, respectively. Changing the mode of administration of orlistat, within the dose regimens investigated, does not affect its pharmacologic efficacy.
Hussain
Y
Y
Pharma Clinical Research, F. Hoffmann-La Roche, Ltd. Basel, Switzerland.
Güzelhan
C
C
Odink
J
J
van der Beek
E J
EJ
Hartmann
D
D
D000042:Absorption; D000328:Adult; D004041:Dietary Fats / Q000378:metabolism*; D004311:Double-Blind Method; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D008049:Lipase / Q000037:antagonists & inhibitors*; D008297:Male; D000077403:Orlistat
D004041:Dietary Fats; D007783:Lactones; D000077403:Orlistat; D008049:Lipase